Gregory Burshtein, PhD

Entera Bio Ltd
Jerusalem, Yerushalayim, Israel

Disclosure information not submitted.

Presentation(s):

• ORF37-02 - Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study

  Sunday, June 14, 2026
  3:30 PM - 4:15 PM CT

• MON-768 - Pre-Clinical Results for EB612: First-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet for Patients with Hypoparathyroidism

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT